Chronic fatigue syndrome: the invisible crisis reshaping UK healthcare

The silent epidemic: why ME/CFS remains Britain’s most neglected illness

Few medical conditions have been as systematically overlooked as myalgic encephalomyelitis (ME), also known as chronic fatigue syndrome (CFS). Affecting an estimated 250,000 people in the UK—with around a quarter so severely ill they are housebound or bedridden—ME/CFS has long been dismissed as psychological, despite growing evidence of its biological roots. This week, environmental campaigner George Monbiot turned his attention to the crisis, revealing a pattern of neglect that persists even as scientific understanding of the disease advances.

Monbiot’s investigation, published in The Guardian, paints a damning picture of a healthcare system that has failed ME/CFS patients for decades. Despite updates to clinical guidelines and mounting research linking the condition to neurological and immune dysfunction, many sufferers report being gaslit by doctors, denied disability benefits, or told their symptoms are "all in their head." The consequences are devastating: careers abandoned, relationships strained, and lives reduced to mere survival.

What makes this crisis particularly striking is its contrast with other chronic illnesses. Conditions like multiple sclerosis or Parkinson’s, which also lack cures, are met with empathy and structured care pathways. ME/CFS, by comparison, remains a battleground—one where patients must fight not only their disease but also the stigma attached to it.

The science is clear. So why the delay?

The disconnect between medical progress and patient experience is glaring. In 2021, the UK’s National Institute for Health and Care Excellence (NICE) updated its guidelines on ME/CFS, explicitly rejecting graded exercise therapy (GET) and cognitive behavioural therapy (CBT) as treatments. The move was hailed as a victory by patient advocates, who had long argued that these approaches worsened symptoms. Yet five years later, many doctors continue to recommend them, and access to specialist care remains patchy.

The reasons for this inertia are complex. ME/CFS lacks a single diagnostic test, making it easier for sceptics to dismiss. Its symptoms—exhaustion, brain fog, post-exertional malaise—are invisible, leaving patients vulnerable to accusations of laziness or hypochondria. And while research into potential biomarkers and treatments has accelerated, funding remains disproportionately low compared to diseases with similar prevalence.

A 2023 report by the UK’s All-Party Parliamentary Group on ME found that the condition receives just £5 million in annual research funding—less than 1% of what is allocated to multiple sclerosis, despite affecting a similar number of people. The disparity speaks volumes about the priorities of a healthcare system stretched thin by austerity and post-pandemic backlogs.

The human cost: voices from the shadows

Behind the statistics are stories of lives derailed. Monbiot’s call for testimonies on social media elicited hundreds of responses, many from people who described being "abandoned" by the NHS. One woman, bedridden for a decade, recounted how her GP told her to "just push through" the fatigue. Another, a former teacher, said she was denied disability benefits after being deemed "fit for work" despite being unable to leave her home.

The psychological toll is profound. Many patients internalise the scepticism they encounter, leading to self-doubt and isolation. "You start to wonder if you’re imagining it," one respondent wrote. "But then you try to stand up and your legs give way."

The crisis extends beyond healthcare. ME/CFS patients are disproportionately affected by welfare cuts, with many losing disability benefits after assessments that fail to account for the condition’s fluctuating nature. A 2022 study by the charity Action for ME found that 80% of patients had experienced a deterioration in their mental health due to the stress of navigating the benefits system.

What’s changing—and what isn’t

There are glimmers of progress. In 2024, the UK government announced a £3.2 million fund to improve ME/CFS services, including the creation of specialist clinics. Yet critics argue the investment is a drop in the ocean compared to the scale of the problem. "It’s a start, but it’s not enough," said Sonya Chowdhury, chief executive of Action for ME. "We need a national strategy, not piecemeal fixes."

Meanwhile, the scientific community is making strides. Researchers at Stanford University recently identified potential biomarkers in ME/CFS patients, raising hopes for a diagnostic test. And in the UK, the DecodeME study—the world’s largest genetic study of the condition—has begun analysing DNA samples from 20,000 patients, with early results expected next year.

Yet for those living with ME/CFS, change cannot come fast enough. "We’re not asking for miracles," one patient told Monbiot. "We’re asking for the same dignity and care afforded to people with other chronic illnesses." Until that happens, the crisis will remain invisible only to those who choose not to see it.